Dear Editor,

Lung cancer treatment is a rapidly evolving and an excellent example of precision medicine. The outcome of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) has improved significantly with recent report showing the survival of 56% at 4 years.\[[@ref1]\] This has been possible due to the availability of effective sequential treatment. One of the important drugs has been lorlatinib. This has found to be effective in second-line setting after crizotinib.\[[@ref2]\] There has been no data from India. We retrospectively analyzed the data of patients receiving lorlatinib in our hospital. Patients diagnosed with ALK-positive advanced NSCLC who have received lorlatinib between January 2018 and February 2019 patients who have progressed on crizotinib were included in the study. Lorlatinib (Pfizer Oncology, Groton, CT, USA) was administered orally in a tablet form at a starting dose of 100 mg once daily continuously in 21-day cycles.

The details of these patients were obtained from the prospective lung cancer audit database that is maintained in the department of medical oncology. Demography (age, gender, comorbidity, and smoking status), disease status, and therapy details were recorded. ALK amplified status was ascertained either by immunohistochemistry (monoclonal antibody D5F3 \[Ventana Medical Systems, Tucson, AZ, USA\]) or fluorescent *in situ* hybridization analysis (Abbott Molecular platform). Response assessment was performed every 2--4 months as per the institutional practice and evaluated by RECIST 1.1 criteria. Toxicity during this period was evaluated in accordance with the Common Terminology Criteria for Adverse Events version 4.02 Lorlatinib (Pfizer Oncology, Groton, CT, USA). Date of disease progression, date of change in treatment, and date of death were recorded. SPSS version 21 was used for analysis, and response rate, progression-free survival (PFS), and overall survival were calculated.

Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} tabulate baseline characteristics and side effects of lorlatinib. The estimated median PFS in our study was 9.0 months (range: 5.6 months--12.3 months) \[[Figure 1](#F1){ref-type="fig"}\]. Out of 9 evaluable patients, 2 (20%) and 5 (50%) has complete and partial responses, respectively \[[Table 1](#T1){ref-type="table"}\]. Our results are comparable to that reported in the literature.\[[@ref2]\] However, median duration of response in our cohort was lesser (9 months) in comparison to that reported in literature (12.5 months). Reason for such discrepant data can be explained in view of lorlatinib used in those with extensive disease progressed on multiple lines of therapy and ongoing responses \[[Table 3](#T3){ref-type="table"}\].

###### 

Baseline characteristics of patients treated with lorlatinib

  Demographic (n=10)                           Patients (n=10)
  -------------------------------------------- -----------------
  Median age, years (range)                    52 (23-67)
  Gender, n (%)                                
   Female                                      5 (50)
   Male                                        5 (50)
  History of smoking/tobacco use, n (%)        
   Yes                                         2 (20)
   No                                          8 (80)
  Histopathology, n (%)                        
   Adenocarcinoma                              6 (60)
   Adenosquamous carcinoma                     2 (20)
   Adenocarcinoma with neuroendocrine          2 (20)
  Comorbidities, n (%)                         
   Diabetes mellitus                           1 (10)
   Hypertension                                1 (10)
   Chronic lung disease                        1 (10)
   Multiple                                    1 (10)
   None                                        6 (60)
  ALK positivity, n (%)                        
   FISH alone                                  1 (10)
   IHC alone                                   1 (10)
   Both                                        8 (80)
  Line of lorlatinib use, n (%)                
   3                                           4 (40)
   4                                           4 (40)
   5                                           1 (10)
   6                                           1 (10)
  Best responses (total evaluable -9), n (%)   
   Complete response                           2 (20)
   Partial response                            5 (50)
   Stable disease                              2 (20)

ALK=Anaplastic lymphoma kinase, FISH=Fluorescent *in situ* hybridization, IHC=Immunohistochemistry

###### 

Adverse effects of lorlatinib

  Adverse event (all grade)   *n (%)*
  --------------------------- ---------
  Transaminitis               5 (50)
  Hypercholesterolemia        7 (70)
  Hypertriglyceridemia        7 (70)
  Anemia                      4 (40)
  Nausea                      5 (50)
  Hypophosphatemia            1 (10)
  Edema                       2 (20)
  Increased lipase/amylase    1 (10)

![Median progression-free survival in patients on lorlatinib of 9.0 months (range: 5.6--12.3 months)](SAJC-8-211-g001){#F1}

###### 

Patient-wise line therapy received with median progression-free survival

  Patient   Age   Sex      First line (PFS\*)   Second line (PFS\*)              Third line (PFS\*)     Fourth line (PFS\*)              Fifth line   Response
  --------- ----- -------- -------------------- -------------------------------- ---------------------- -------------------------------- ------------ ---------------
  1         51    Female   Crizotinib (21)      Ceritinib (2)                    Pem-Carbo^\#^ (7)      Gemcitabine (1)                  Lorlatinib   Not evaluated
  2         67    Male     Crizotinib (16)      Ceritinib (4)                    Lorlatinib (11)        Ongoing                                       Complete
  3         57    Female   Pem-Carbo^\#^ (3)    Crizotinib (15)                  Ceritinib (3)          Pem-Carbo^\#^ + crizotinib (2)   Lorlatinib   Partial
  4         64    Female   Pem-Carbo^\#^ (4)    Crizotinib (13)                  Ceritinib (25)         Lorlatinib (5)                   Ongoing      Complete
  5         64    Male     Crizotinib (8)       Ceritinib (16)                   Lorlatinib (3)         Ongoing                                       Stable
  6         28    Male     Crizotinib (20)      Ceritinib (3)                    Lorlatinib (9)         Ongoing                                       Partial
  7         44    Male     Pem-Carbo^\#^ (18)   Crizotinib (20)                  Ceritinib (2)          Lorlatinib                       Ongoing      Partial
  8         54    Male     Crizotinib (13)      Ceritinib (3)                    Lorlatinib (ongoing)                                                 Partial
  9         39    Female   Pem-Carbo^\#^ (7)    Docetaxel (2)                    Ceritinib (3)          Lorlatinib                       Ongoing      Partial
  10        23    Female   Crizotinib (9)       Pem-Carbo^\#^ + crizotinib (2)   Ceritinib (4)          Lorlatinib (6)                   alectinib    Stable

\*Months, \#Pemetrexed and carboplatin combination chemotherapy. PFS=Progression-free survival

We report clinical outcomes on patients with crizotinib-resistant disease treated with lorlatinib and find it an important new treatment option for those patients whose disease has progressed after treatment with crizotinib or second-generation ALK tyrosine kinase inhibitors.
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